FindTrial
Sign In

To assess the effectiveness of 0.1% brimonidine eyedrop instilled before surgery in controlling bleeding in eye during vitrectomy surgery in diabetic patients.

To evaluate the efficacy of preoperative 0.1% brimonidine in achieving hemostasis in diabetic vitrectomy.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046415
Enrollment
80
Registered
2022-10-12
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H350- Background retinopathy and retinalvascular changes

Interventions

Intervention1: Evaluation of hemostasis in diabetic vitrectomy patients with 0.1% topical brimonidine instilled preoperatively 3 times a day for two days with last drop instilled within 4-6 hours of s

Sponsors

Sankara Eye Hospital Bangalore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Advanced diabetic eye disease requiring vitrectomy (S/P scatter photocoagulation) 2. HbA1c - 7-11% 3.Hb - male: >12mg/dl female: >11mg/dl 4.aPTT: 21-35 seconds 5.Adequately controlled renal status 6. age >18yrs 7. BP < 150/90 mmHg on day of surgery

Exclusion criteria

Exclusion criteria: 1. NVG 2. Poor diabetic control 3. Anti -VEFF in last 6weeks

Design outcomes

Primary

MeasureTime frame
1. Duration of Surgery 2. Assessment of intraoperative bleed a. Need for increasing IOP b. Number of bleeders requiring diathermy c. Need for using PFCL d. Clot formation e. Size of clot formation f. Number of tool exchangeTimepoint: Baseline—

Secondary

MeasureTime frame
1. Volume of infusion fluid used 2. Ease of surgery( surgeons grading) 3. Number of Iatrogenic breaksTimepoint: Baseline—

Countries

India

Contacts

Public ContactPriya Jain

Sankara Eye Hospital, Bangalore

drragraj@gmail.com9036952706

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026